©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Sep 19, 2022; 12(9): 1150-1168
Published online Sep 19, 2022. doi: 10.5498/wjp.v12.i9.1150
Published online Sep 19, 2022. doi: 10.5498/wjp.v12.i9.1150
Depressive disorder and antidepressants from an epigenetic point of view
Iris Šalamon Arčan, Katarina Kouter, Alja Videtič Paska, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana SI-1000, Slovenia
Author contributions: Videtič Paska A and Šalamon Arčan I organized and planned the manuscript; Šalamon Arčan I wrote the first draft of the manuscript; Kouter K and Videtič Paska A reviewed and edited the manuscript; All authors approved the final version of the manuscript.
Supported by Slovenina Reserach Agency , Young Researcher Grant to IŠ, No. P1-0390.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Alja Videtič Paska, PhD, Associate Professor, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, Ljubljana SI-1000, Slovenia. alja.videtic@mf.uni-lj.si
Received: March 25, 2022
Peer-review started: March 25, 2022
First decision: May 11, 2022
Revised: May 27, 2022
Accepted: August 6, 2022
Article in press: August 6, 2022
Published online: September 19, 2022
Processing time: 178 Days and 15.2 Hours
Peer-review started: March 25, 2022
First decision: May 11, 2022
Revised: May 27, 2022
Accepted: August 6, 2022
Article in press: August 6, 2022
Published online: September 19, 2022
Processing time: 178 Days and 15.2 Hours
Core Tip
Core Tip: Deeper knowledge on the biological background of depressive disorder could be achieved through understanding of epigenetic mechanisms that alter the response of cells to environmental stimuli. Antidepressants are of particular interest since it has been shown that they affect DNA methylation, histone modifications, and microRNA expression. As not all patients respond to prescribed antidepressants, it is of interest to discover specific biomarkers that could be used in a clinical setting.